Topics

Glioblastoma | Outcomes | Dendritic-cell-based vaccine

Home > Publications > Topics > Glioblastoma > Outcomes > Dendritic cells

Berneman ZN, De Laere M, Germonpré P, Huizing MT, Willemen Y, Lion E, De Reu H, Van den Bossche J, Van den Brande J, Specenier P, Altintas S, van Dam PA, Cools N, Nijs G, Stein B, Caluwaerts K, Snoeckx A, Op de Beeck B, Saevels K, Rutsaert L, Vandenbosch I, Oner G, Lammens M, Van Damme P, Llewellyn-Lacey S, Price DA, Oka Y, Oji Y, Sugiyama H, Couttenye MM, Van de Velde AL, Van Tendeloo VF, Peeters M, Anguille S, Smits ELJM.
WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome.
J Hematol Oncol. 2025 Jan 23;18(1):9. doi: 10.1186/s13045-025-01661-x. PMID: 39849594. Interventional study. ˍ